15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

(2012) Hashem B. El-Serag   GASTROENTEROLOGY

Prostaglandin catabolic enzymes as tumor suppressors

(2011) Hsin-Hsiung Tai   CANCER AND METASTASIS REVIEWS

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors

(2011) Natalia G. Starostina et al.   TRENDS IN CELL BIOLOGY

Loss of 15-Hydroxyprostaglandin Dehydrogenase Expression Contributes to Bladder Cancer Progression

(2010) Stephanie Tseng-Rogenski et al.   AMERICAN JOURNAL OF PATHOLOGY

Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk

(2010) B. Frank et al.   CARCINOGENESIS

Examination of the expanding pathways for the regulation of p21 expression and activity

(2010) Yong-Sam Jung et al.   CELLULAR SIGNALLING

PPARγ: a circadian transcription factor in adipogenesis and osteogenesis

(2010) Masanobu Kawai et al.   Nature Reviews Endocrinology

Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma

(2009) Hiroshi Tatsuwaki et al.   CANCER SCIENCE

HGF/Met signalling promotes PGE2 biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells

(2009) A. E. Moore et al.   CARCINOGENESIS

15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric Cancer

(2009) A. Thiel et al.   CLINICAL CANCER RESEARCH

Altered Expression of 15-Hydroxyprostaglandin Dehydrogenase in Tumor-Infiltrated CD11b Myeloid Cells: A Mechanism for Immune Evasion in Cancer

(2009) E. Eruslanov et al.   JOURNAL OF IMMUNOLOGY

Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression

(2009) L. N. Kaliberova et al.   MOLECULAR CANCER THERAPEUTICS

Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking  -catenin and cyclooxygenase-2

(2009) K. Lim et al.   MOLECULAR CANCER THERAPEUTICS

15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors

(2009) M. Yan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fat and Beyond: The Diverse Biology of PPARγ

(2008) Peter Tontonoz et al.   Annual Review of Biochemistry

Repression of 15-Hydroxyprostaglandin Dehydrogenase Involves Histone Deacetylase 2 and Snail in Colorectal Cancer

(2008) M. G. Backlund et al.   CANCER RESEARCH

Nonsteroidal Anti-inflammatory Drugs Suppress Glioma via 15-Hydroxyprostaglandin Dehydrogenase

(2008) N. Wakimoto et al.   CANCER RESEARCH

15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3  and a Tumor Suppressor in Lung Cancer

(2008) G. Huang et al.   CANCER RESEARCH

Cyclooxygenase-2 Derived Prostaglandin E2 Activates -Catenin in Human Cholangiocarcinoma Cells: Evidence for Inhibition of These Signaling Pathways by  3 Polyunsaturated Fatty Acids

(2008) K. Lim et al.   CANCER RESEARCH

Expression of 15-PGDH is downregulated by COX-2 in gastric cancer

(2008) Z. Liu et al.   CARCINOGENESIS

Molecular targeted therapies in hepatocellular carcinoma

(2008) Josep M. Llovet et al.   HEPATOLOGY